Cisplatin Shortage Results In Substitution of More Expensive Treatments: Drug Cost Analysis
Dear Editor, (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 16, 2024 Category: Cancer & Oncology Authors: Michael Lam, Timoth ée Olivier, Alyson Haslam, Jordan Tuia, Vinay Prasad Tags: Letter to the Editor Source Type: research
Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colo-rectal cancer patients
This retrospective study determined survival responses to immune checkpoint inhibitors (ICIs), comparing mono- (mono) and combo-immunotherapy (combo) in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) by analyzing quantitative imaging data and clinical factors. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 15, 2024 Category: Cancer & Oncology Authors: R émy Barbe, Younes Belkouchi, Yves Menu, Romain Cohen, Clemence David, Michele Kind, Sana Harguem, Lama Dawi, Joya Hadchiti, Fatine Selhane, Nicolas Billet, Samy Ammari, Ambroise Bertin, Littisha Lawrance, Baptiste Cervantes, Antoine Hollebecque, Corinn Tags: Original Research Source Type: research
Clinical care pathways of patients with biliary tract cancer: A French Nationwide Longitudinal Cohort Study
Although the incidence of BTC is raising, national healthcare strategies to improve care lack. We aimed to explore patient clinical care pathways and strategies to improve biliary tract cancer (BTC) care. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 15, 2024 Category: Cancer & Oncology Authors: Stylianos Tzedakis, Alexandre Challine, Sandrine Katsahian, David Malka, Romain Jaquet, Ugo Marchese, Martin Gaillard, Romain Coriat, Alix Dhote, Vincent Mallet, Heithem Jeddou, Karim Boudjema, David Fuks, Andrea Lazzati Tags: Original Research Source Type: research
A recurrent NTRK1 tyrosine kinase domain mutation pair is characteristic in a subset of dedifferentiated liposarcomas
Dedifferentiated liposarcoma (DDLPS) is a common form of liposarcoma with challenging treatment modalities. Pan-TRK immunopositivity can be often observed without NTRK gene fusion in soft tissue sarcomas with myogenic differentiation. Expression and the role of NTRK in DDLPS are under-studied. We sought to identify activating mutations of the NTRK genes. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 13, 2024 Category: Cancer & Oncology Authors: Zolt án Lippai, Bálint Péterfia, Gergő Papp, Katalin Dezső, Gábor Bedics, Zsuzsanna Pápai, Meindert H Lamers, Rosan CM Kuin, Károly Szuhai, Zoltán Sápi Tags: Original Research Source Type: research
Editorial Board
(Source: European Journal of Cancer)
Source: European Journal of Cancer - March 12, 2024 Category: Cancer & Oncology Source Type: research
Biliary Tract Cancers: French National Clinical Practice Guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)
This document is a summary of the French intergroup guidelines of the management of biliary tract cancers (BTC) (intrahepatic, perihilar and distal cholangiocarcinomas, and gallbladder carcinomas) published in September 2023, available on the website of the French Society of Gastroenterology (SNFGE) (www.tncd.org). (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 12, 2024 Category: Cancer & Oncology Authors: Gael S Roth, Loic Verlingue, Matthieu Sarabi, Jean-Fr édéric Blanc, Emmanuel Boleslawski, Karim Boudjema, Anne-Laure Bretagne-Bignon, Marine Camus-Duboc, Romain Coriat, Gilles Créhange, Thierry De Baere, Christelle de la Fouchardière, Clarisse Dromain Source Type: research
Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?
This study presents the chemo-immunotherapy experience in patients with relapsed/progressive high-risk neuroblastoma treated within the off-label use program of the Neuroblastoma Committee of the French Society of Pediatric Oncology (SFCE). (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 11, 2024 Category: Cancer & Oncology Authors: Patricia Raiser, Gudrun Schleiermacher, Marion Gambart, Benoit Dumont, Anne-Sophie Defachelles, Estelle Thebaud, Julie Tandonnet, Claudia Pasqualini, St éphanie Proust, Natacha Entz-Werle, Isabelle Aerts, Lee A. Ndounga-Diakou, Arnaud Petit, Chloe Puiseu Tags: Original Research Source Type: research
A Global Phase II Randomized trial comparing Oral Taxane ModraDoc006/r to Intravenous Docetaxel in Metastatic Castration Resistant Prostate Cancer
ModraDoc006, an oral formulation of docetaxel, is co-administered with the cytochrome P450-3A4 and P-glycoprotein inhibitor, ritonavir (r): ModraDoc006/r. The preliminary efficacy and safety of oral ModraDoc006/r was evaluated in a global randomized phase II trial and compared to the current standard chemotherapy regimen of intravenous (i.v.) docetaxel and prednisone. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 9, 2024 Category: Cancer & Oncology Authors: Ulka N. Vaishampayan, Marianne Keessen, Robert Dreicer, Elisabeth I. Heath, Tomas Buchler, P éter F. Árkosy, CsosziTibor Csöszi, Pawel Wiechno, Evgeny Kopyltsov, Sergey V. Orlov, Alexey Plekhanov, Maria Smagina, Sergei Varlamov, Neal D. Shore Tags: Original Research Source Type: research
Corrigendum to “Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial” [Eur J Cancer 199 (2024) 113531]
The authors regret to notify a change to an author institution detail in this manuscript. Professor Marchetti requests to correct their institution information From: Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy - To: Istituto Dermopatico dell'Immacolata IDI IRCCS, Rome, Italy. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 9, 2024 Category: Cancer & Oncology Authors: Anna Maria Di Giacomo, Vanna Chiarion-Sileni, Michele Del Vecchio, Pier Francesco Ferrucci, Michele Guida, Pietro Quaglino, Massimo Guidoboni, Paolo Marchetti, Elena Simonetti, Federica Santangelo, Giovanni Amato, Alessia Covre, Roberto Camerini, Monica V Tags: Corrigendum Source Type: research
Assessing the clinical benefit of systemic anti-cancer treatments in the Netherlands: the impact of different thresholds for effectiveness
In the Netherlands, the clinical benefit of systemic anti-cancer treatments (SACTs) is assessed by the Committee for the Evaluation of Oncological Agents (cieBOM). For non-curative SACTs, the assessment is based on the hazard ratio (HR) for progression-free survival and/or overall survival (OS), and the difference in median survival. We evaluated the impact of different thresholds for effectiveness by reassessing the clinical benefit of SACTs. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 9, 2024 Category: Cancer & Oncology Authors: Brenda Leeneman, Nicolas S.H. Xander, W. Edward Fiets, Wouter K. de Jong, Nathalie E.M. Uyl, A.N. Machteld Wymenga, An K.L. Reyners, Carin A. Uyl-de Groot Tags: Original Research Source Type: research
How to develop new systemic treatments in ultra-rare cancers with high unmet needs? The case of alveolar soft-part sarcoma.
Developing new drugs or generating evidence for existing drugs in new indications for ultra-rare cancers is complex and carries a high-risk of failure. This gets even harder in ultra-rare tumours, which have an annual incidence of 1 per 1,000,000 population or less. Here, we illustrate the problem of adequate evidence generation in ultra-rare tumours, using Alveolar Soft-Part Sarcomas (ASPS) – an ultra-rare sarcoma newly diagnosed in approximately 60 persons a year in the European Union – as an exemplar case showing challenges in development despite being potentially relevant for classes of agents. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 9, 2024 Category: Cancer & Oncology Authors: Silvia Stacchiotti, Gauthier Bouche, Ralf Herold, Pan Pantziarka, Kathrin Schuster, Roger Wilson, Francesco Pignatti, Bernd Kasper Tags: Current Perspective Source Type: research
Prognosis of glioblastoma patients improves significantly over time interrogating historical controls
Glioblastoma (GBM) is the most common devastating primary brain cancer in adults. In our clinical practice, median overall survival (mOS) of GBM patients seems increasing over time. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 9, 2024 Category: Cancer & Oncology Authors: A Thomas, S Tran, L El Houari, A Seyve, F Bielle, C Birzu, F Lozano-Sanchez, K Mokhtari, M Giry, Y Marie, F Laigle-Donadey, C Dehais, C Houillier, D Psimaras, A Alentorn, A Laurenge, M Touat, M Sanson, K Hoang-Xuan, A Kas, L Rozenblum, M-O Habert, L Niche Source Type: research
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
The aim of this multi-center, retrospective/prospective cohort observational study was to evaluate outcomes in routine clinical practice of first-line chemo-immunotherapy with cis/carboplatin, pemetrexed and pembrolizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC) in 33 Italian centers. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 9, 2024 Category: Cancer & Oncology Authors: Leonetti Alessandro, Perrone Fabiana, Puntoni Matteo, Maglietta Giuseppe, Bordi Paola, Bria Emilio, Vita Emanuele, Gelsomino Francesco, De Giglio Andrea, Gelibter Alain, Siringo Marco, Mazzoni Francesca, Caliman Enrico, Genova Carlo, Bertolini Federica, G Source Type: research
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
Tunlametinib showed promising antitumor activity with a manageable safety profile in patients with advanced NRAS-mutant melanoma, including those who had prior exposure to immunotherapy. The findings warrant further validation in a randomized clinical trial. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 9, 2024 Category: Cancer & Oncology Authors: Xiaoting Wei, Zhengyun Zou, Weizhen Zhang, Meiyu Fang, Xiaoshi Zhang, Zhiguo Luo, Jing Chen, Gang Huang, Peng Zhang, Ying Cheng, Jiwei Liu, Jiyan Liu, Junping Zhang, Di Wu, Yu Chen, Xiaobiao Ma, Hongming Pan, Renbing Jiang, Xinlan Liu, Xiubao Ren, Hongqi Source Type: research
A three-arm randomised Phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma
The MAPK pathway is constitutively activated in uveal melanoma (UM). Selumetinib (AZD6244, ARRY-142886), a MEK inhibitor, has shown limited activity as monotherapy in metastatic UM. Pre-clinical studies support synergistic cytotoxic activity for MEK inhibitors combined with taxanes, and here we sought to assess the clinical efficacy of combining selumetinib and paclitaxel. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 9, 2024 Category: Cancer & Oncology Authors: Joseph J Sacco, Richard Jackson, Pippa Corrie, Sarah Danson, T.R. Jeffry Evans, Sebastian Ochsenreither, Satish Kumar, Andrew Goodman, James Larkin, Ioannis Karydis, Neil Steven, Paul Lorigan, Ruth Plummer, Poulam Patel, Eftychia Psarelli, Anna Olsson-Bro Tags: Clinical Trial Source Type: research
